20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. is asking stockholders to authorize its board, in its discretion, to implement one or more reverse stock splits at ratios from 1-for-2 to 1-for-250 before December 31, 2028. An approved split would reduce the number of common shares outstanding, with fractional shares rounded up; the par value would remain $0.01 per share. A split would take effect upon filing an amendment with Delaware.
The company says it intends to use a reverse split to address Nasdaq’s bid-price deficiency. It received notice on July 17, 2026, after failing the $1.00 closing bid-price requirement for 30 consecutive business days from June 3 through July 16, 2026. The first compliance period runs through January 13, 2027; the closing bid must be at least $1.00 for 10 consecutive business days. A second 180-calendar-day period may be available subject to additional listing standards and written notice; the company says there is no assurance it will regain compliance.
At the December 9, 2026 virtual special meeting, stockholders will also vote on authority to adjourn if additional proxies are needed. There were 13,367,204 common shares outstanding as of October 20, 2026, each carrying one vote. The board recommends voting “FOR” both proposals.
20/20 Biolabs, Inc. is asking stockholders to authorize its board, in its discretion, to effect one or more reverse stock splits at a cumulative ratio from 1-for-2 to 1-for-250 at any time prior to December 31, 2028. The board would choose whether and when to implement a split and the ratio; approval would not itself effect a split. Fractional shares would be rounded up to the nearest whole share. A second proposal asks stockholders to authorize meeting adjournments, if needed, to solicit more votes for the split. The board recommends a FOR vote on both proposals at the virtual meeting on December 9, 2026.
20/20 Biolabs says it intends to use a reverse split to address Nasdaq’s bid-price requirement. Nasdaq notified the company on July 17, 2026 that it was not in compliance with the $1.00 closing bid-price requirement for 30 consecutive business days from June 3 through July 16, 2026. To regain compliance by January 13, 2027, its closing bid must be at least $1.00 per share for 10 consecutive business days. If the company does not regain compliance within the allotted periods, including any extensions Nasdaq may grant, Nasdaq will provide notice that its common stock will be subject to delisting. The company says a reverse split would not assure compliance or a sustained share-price increase.
20/20 Biolabs, Inc. (AIDX) reports that stockholders approved a charter amendment at the adjourned annual meeting held on September 16, 2026. The amendment increases the number of shares of common stock the company is authorized to issue from 50 million to 500 million.
As of the June 22, 2026 record date, 12,251,198 shares of common stock were outstanding and entitled to vote, and 4,256,837 shares were represented in person or by proxy, constituting a quorum. Proposal 3 passed with 3,028,609 votes for, 1,155,607 against, and 72,621 abstentions.
20/20 Biolabs, Inc. (AIDX) reports that it has received Nasdaq deficiency notices related to both the minimum bid price and stockholders’ equity listing standards. The company previously entered a 180-day period, ending January 13, 2027, to regain compliance with the $1.00 minimum bid price by maintaining that level for at least 10 consecutive business days. On September 3, 2026, Nasdaq also notified the company that it is below the $2,500,000 stockholders’ equity requirement, after the June 30, 2026 Form 10-Q reported stockholders’ equity of $1,620,700. 20/20 Biolabs has 45 days from the September 3 notice to submit a compliance plan, and may receive up to an additional 180 days if the plan is accepted, but faces potential delisting if it fails to regain compliance.
20/20 Biolabs, Inc. (NASDAQ: AIDX) furnished an investor webinar presentation outlining its multi-cancer early detection strategy, regulatory engagement, and commercial progress for its OneTest platform. The materials emphasize integration of serial biomarker testing, machine learning, and anti-inflammatory lifestyle interventions, and discuss potential positioning for future Medicare coverage of multi-cancer early detection blood tests beginning in 2028.
The company reports that Q2 2026 produced its best quarterly cancer testing revenue to date, with a 47% year-over-year increase, driven by 29 orders from new occupational health and clinical accounts and expanding firefighter screening programs in Maryland and Vermont. 20/20 Biolabs also describes preliminary, non-binding discussions with senior FDA personnel about evidence generation and potential regulatory pathways, and outlines planned next steps including formal interactions such as informational meetings, possible Breakthrough Device designation requests, and Q-Submissions, while cautioning that requirements, timing, and outcomes may differ materially from current expectations.
20/20 Biolabs, Inc. (AIDX) reported the results of its August 18, 2026 annual stockholders meeting held via webcast. Stockholders of record on June 22, 2026, holding 12,251,198 common shares, were entitled to vote, and 4,256,837 shares were represented, constituting a quorum.
Six directors were elected, each receiving roughly 2.65–2.73 million votes for and about 156–176 thousand votes withheld, with 1,433,721 broker non-votes on each director. Stockholders ratified dbbmckennon as independent registered public accounting firm for 2026 with 4,105,584 votes for, 132,421 against, and 18,832 abstentions. They also approved the 2026 Equity Incentive Plan with 2,183,335 votes for, 573,931 against, 65,850 abstentions, and 1,433,721 broker non-votes, and approved the ability to adjourn the meeting if needed, by 3,037,106 votes for, 1,132,166 against, and 87,565 abstentions. A charter amendment proposal did not receive sufficient votes and the meeting was adjourned on that item to September 16, 2026.
20/20 Biolabs, Inc. is updating its resale registration covering up to 15,164,724 shares of common stock held by certain selling stockholders, incorporating its quarterly results for the period ended June 30, 2026.
For the quarter, revenue rose to $730,571 from $535,060, driven mainly by higher OneTest cancer-screening sales, especially to Maryland firefighter programs. Gross margin improved to 41.71% from 30.51%. However, higher public-company, stock-based compensation and investor-relations costs pushed operating expenses to $1.55 million, widening the quarterly net loss to $1.51 million versus $0.84 million a year earlier.
For the first six months, revenue was essentially flat at $1.08 million, while the net loss increased to $3.68 million from $1.61 million, reflecting increased operating and financing costs, including losses tied to convertible notes and warrant-related derivatives. As of June 30, 2026, the company held $4.55 million in cash and cash equivalents and $2.52 million in working capital, supported by a $6.0 million Series E preferred stock financing and related convertible debt transactions. Management notes recent losses may continue and that failure to secure adequate capital could eventually force a cessation of operations.
20/20 Biolabs, Inc. is updating a resale registration statement covering up to 10,105,000 shares of common stock held by selling stockholders, while incorporating its quarterly results for the period ended June 30, 2026. The common stock trades on Nasdaq under “AIDX,” closing at $0.549 on August 14, 2026, with 12,770,303 shares outstanding.
For the second quarter, revenue rose to $730,571, up 36.54% year over year, driven mainly by 47.08% growth in OneTest sales, while quarterly gross margin improved to 41.71%. However, higher public-company and growth-related costs pushed the quarterly net loss to $1,506,343; the six‑month net loss reached $3,681,180.
Liquidity improved through a $6,000,000 private placement of Series E convertible preferred stock, lifting cash to $4,546,140 and working capital to $2,524,386. As of June 30, 2026, 5,228 Series E preferred shares were outstanding, senior to common stock and convertible into common shares, alongside 3,656,172 outstanding warrants, creating potential future dilution.
20/20 BioLabs, Inc. reported strong top-line improvement for the quarter ended June 30, 2026. Revenue rose 36.5% to $730,571 from $535,060, driven by OneTest™ multi-cancer early detection blood tests, which increased 47.1% to $697,034 and represented 95.3% of total revenue.
Gross profit grew 86.6% to $304,727, with gross margin expanding to 41.7% from 30.5%, reflecting favorable mix and better fixed-cost absorption. However, operating expenses increased to $1.55 million from $1.01 million, largely due to Nasdaq listing costs and product development spend, leading to a quarterly net loss of $1.51 million versus $0.84 million a year earlier.
For the first half of 2026, revenue was essentially flat at $1.08 million, while net loss widened to $3.68 million. Liquidity improved meaningfully: cash rose to $4.55 million at June 30, 2026 from $1.03 million at year-end 2025, primarily from $6.0 million of Series E preferred financing, and all convertible note debt was eliminated. Stockholders’ equity turned positive at $1.62 million from a slight deficit.
20/20 Biolabs, Inc. reported higher Q2 2026 revenues but significantly larger losses. Revenue for the quarter was $730,571, up 36.5% year over year, driven mainly by strong growth in OneTest sales, particularly from Maryland firefighter cancer screening programs. Q2 gross margin improved to 41.71% from 30.51% as lab fixed costs were leveraged over higher volumes.
For the six months ended June 30, 2026, revenue was $1,083,946, roughly flat with 2025, while the net loss widened to $3,681,180 from $1,605,511 due to higher public-company and listing-related expenses, increased research and development, and financing-related costs including interest and derivative losses. Cash and cash equivalents rose to $4,546,140, supported by a $6 million Series E preferred private placement and new convertible debt, giving working capital of $2,524,386.
Management notes recent operating losses are expected to continue near term and states that if additional capital cannot be obtained, operations could cease, indicating going concern uncertainty despite the recent capital raises. Capital structure became more complex, with legacy preferred shares and convertible notes converted into common stock and 5,228 shares of Series E convertible preferred stock outstanding plus 3.66 million warrants.